^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GNC-039

    i
    Other names: GNC-039, GNC039, GNC 039
    Associations

    News

    Trials
    Company:
    Biokin Pharma
    Drug class:
    PD-L1 inhibitor, CD3 agonist, CD137 agonist, EGFRvIII inhibitor
    Related drugs:
    Associations

    News

    Trials
    28d
    A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=147, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Oct 2024 --> Jun 2025 | Trial primary completion date: Oct 2024 --> Jun 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    GNC-039
    5ms
    A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=147, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Jun 2024 --> Oct 2024 | Trial primary completion date: Jun 2024 --> Oct 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    GNC-039
    10ms
    A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=147, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Dec 2023 --> Jun 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    GNC-039
    12ms
    A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=147, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd.
    Trial completion date • Trial primary completion date • Metastases
    |
    GNC-039
    almost2years
    Tetra-specific antibody GNC-039: guidance and navigation control (GNC) molecule development for treatment of EGFRvIII+ malignancies (AACR 2023)
    Groups received either GNC-039 (n=5), GNC-039 with engrafted PBMC (n=5), Temozolomide(n=5), or Vehicle (n=5). However, beyond this timepoint, the level of GNC-039 in the brain region was significantly increased due to the engrafted PBMC.Collectively this data indicates the functionality of GNC-039 as a multi-specific T cell engager with the potential to target EGFRvIII+ cancer cell cytolysis in primary brain disease. The clinical phase I-b study of GNC-039 is under way and the available data exhibit strong signals of efficacy with acceptable tolerability.
    PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    EGFRvIII expression
    |
    temozolomide • GNC-039